Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Intervalo de ano de publicação
1.
Br J Nutr ; 110(7): 1272-84, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23510814

RESUMO

Paraoxonase 1 (PON1) is associated with HDL and modulates the antioxidant and anti-inflammatory role of HDL. The goals of the present study were to investigate the effect of ageing and the role of PON1 on the anti-inflammatory activity of HDL, and to determine whether extra-virgin olive oil (EVOO) consumption could improve the atheroprotective activity of HDL. HDL and PON1 were isolated from the plasma of ten young (Y-HDL and Y-PON1) and ten elderly (E-HDL and E-PON1) healthy volunteers before and after 12 weeks of EVOO consumption. Inflammation was assessed by measuring intracellular adhesion molecule 1 (ICAM-1) expression. THP-1 (human acute monocytic leukaemia cell line) monocyte chemotaxis was measured using a Boyden chamber. Oxidative damage to HDL was assessed by measuring conjugated diene formation and changes in electrophoretic migration. Y-HDL had more anti-inflammatory activity than E-HDL. The conjugated diene content and the electrophoretic mobility of E-HDL were higher than those of Y-HDL. Y-PON1 had significant anti-inflammatory activity, reducing ICAM-1 expression by 32·64 (SD 2·63)%, while E-PON1 had no significant effect. THP-1 chemotaxis measurements confirmed the ICAM-1 expression results. The 12 weeks of EVOO consumption significantly increased the anti-inflammatory activities of both HDL and PON1. The anti-inflammatory activity of HDL was modulated by PON1 and was lower in the elderly volunteers. EVOO consumption increased the anti-inflammatory effect of HDL and reduced the age-related decrease in anti-atherogenic activity.


Assuntos
Envelhecimento/metabolismo , Anti-Inflamatórios/uso terapêutico , Arildialquilfosfatase/metabolismo , Gorduras na Dieta/uso terapêutico , Inflamação/prevenção & controle , Lipoproteínas HDL/metabolismo , Óleos de Plantas/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Inflamatórios/farmacologia , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Quimiotaxia , Dieta , Gorduras na Dieta/farmacologia , Feminino , Humanos , Inflamação/metabolismo , Molécula 1 de Adesão Intercelular/metabolismo , Masculino , Doenças Metabólicas/prevenção & controle , Monócitos , Olea/química , Azeite de Oliva , Estresse Oxidativo/efeitos dos fármacos , Óleos de Plantas/farmacologia , Adulto Jovem
2.
Nutrients ; 15(23)2023 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-38068738

RESUMO

Modern research achievements support the health-promoting effects of natural products and diets rich in polyphenols. Pomegranate (PG) (Punica granatum L.) contains a considerable number of bioactive compounds that exert a broad spectrum of beneficial biological activities, including antimicrobial, antidiabetic, antiobesity, and atheroprotective properties. In this context, the reviewed literature shows that PG intake might reduce insulin resistance, cytokine levels, redox gene expression, blood pressure elevation, vascular injuries, and lipoprotein oxidative modifications. The lipid parameter corrective capabilities of PG-ellagitannins have also been extensively reported to be significantly effective in reducing hyperlipidemia (TC, LDL-C, VLDL-C, and TAGs), while increasing plasma HDL-C concentrations and improving the TC/HDL-C and LDL-C/HDL-C ratios. The health benefits of pomegranate consumption seem to be acheived through the amelioration of adipose tissue endocrine function, fatty acid utilization, GLUT receptor expression, paraoxonase activity enhancement, and the modulation of PPAR and NF-κB. While the results from animal experiments are promising, human findings published in this field are inconsistent and are still limited in several aspects. The present review aims to discuss and provide a critical analysis of PG's bioeffects on the components of metabolic syndrome, type-2 diabetes, obesity, and dyslipidemia, as well as on certain cardiovascular-related diseases. Additionally, a brief overview of the pharmacokinetic properties, safety, and bioavailability of PG-ellagitannins is included.


Assuntos
Lythraceae , Síndrome Metabólica , Punica granatum , Animais , Humanos , Polifenóis/farmacologia , Polifenóis/uso terapêutico , Polifenóis/análise , Síndrome Metabólica/tratamento farmacológico , Síndrome Metabólica/prevenção & controle , Taninos Hidrolisáveis/farmacologia , LDL-Colesterol , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Extratos Vegetais/análise
3.
Nutrients ; 13(7)2021 Jun 29.
Artigo em Inglês | MEDLINE | ID: mdl-34209930

RESUMO

High-density lipoproteins (HDL) maintain cholesterol homeostasis through the role they play in regulating reverse cholesterol transport (RCT), a process by which excess cholesterol is transported back to the liver for elimination. However, RCT can be altered in the presence of cardiovascular risk factors, such as aging, which contributes to the increase in the incidence of cardiovascular diseases (CVD). The present study was aimed at investigating the effect of extra virgin olive oil (EVOO) intake on the cholesterol efflux capacity (CEC) of HDL, and to elucidate on the mechanisms by which EVOO intake improves the anti-atherogenic activity of HDL. A total of 84 healthy women and men were enrolled and were distributed, according to age, into two groups: 27 young (31.81 ± 6.79 years) and 57 elderly (70.72 ± 5.6 years) subjects. The subjects in both groups were given 25 mL/d of extra virgin olive oil (EVOO) for 12 weeks. CEC was measured using J774 macrophages radiolabeled with tritiated cholesterol ((3H) cholesterol). HDL subclass distributions were analyzed using the Quantimetrix Lipoprint® system. The HDL from the elderly subjects exhibited a lower level of CEC, at 11.12% (p < 0.0001), than the HDL from the young subjects. The CEC of the elderly subjects returned to normal levels following 12 weeks of EVOO intake. An analysis of the distribution of HDL subclasses showed that HDL from the elderly subjects were composed of lower levels of large HDL (L-HDL) (p < 0.03) and higher levels of small HDL (S-HDL) (p < 0.002) compared to HDL from the young subjects. A multiple linear regression analysis revealed a positive correlation between CEC and L-HDL levels (r = 0.35 and p < 0.001) as well as an inverse correlation between CEC and S-HDL levels (r = -0.27 and p < 0.01). This correlation remained significant even when several variables, including age, sex, and BMI as well as low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and glucose levels (ß = 0.28, p < 0.002, and ß = 0.24, p = 0.01) were accounted for. Consuming EVOO for 12 weeks modulated the age-related difference in the distribution of HDL subclasses by reducing the level of S-HDL and increasing the level of intermediate-HDL/large-HDL (I-HDL/L-HDL) in the elderly subjects. The age-related alteration of the CEC of HDL was due, in part, to an alteration in the distribution of HDL subclasses. A diet enriched in EVOO improved the functionality of HDL through an increase in I-HDL/L-HDL and a decrease in S-HDL.


Assuntos
Envelhecimento/sangue , Aterosclerose/prevenção & controle , Doenças Cardiovasculares/prevenção & controle , Lipoproteínas HDL/sangue , Azeite de Oliva/administração & dosagem , Adulto , Idoso , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Feminino , Voluntários Saudáveis , Humanos , Masculino
4.
Pharmacol Res ; 54(1): 1-5, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16554174

RESUMO

AIM: The argan oil, extracted from argan-tree fruits, has been known for its various pharmacological properties and used as a natural remedy since several centuries. In this review, we present a summary of the results obtained from a survey of the literature on argan oil. DATA SYNTHESIS: Various studies conducted in vitro or on human and animal models suggest that argan oil could play a beneficial role in cardiovascular diseases prevention and its consumption could protect against atherosclerosis and cancer via a variety of biological mechanisms. CONCLUSION: Argan oil reduces cardiovascular risk and may be used as anti-atherogenic oil.


Assuntos
Doenças Cardiovasculares/prevenção & controle , Óleos de Plantas/farmacologia , Sapotaceae/química , Animais , Anti-Hipertensivos/farmacologia , Antioxidantes/análise , Antioxidantes/farmacologia , Ácidos Graxos Insaturados/análise , Frutas/química , Humanos , Hipolipemiantes/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA